Menu
Search
|

Menu

Close
X

Momenta Pharmaceuticals Inc MNTA.OQ (NASDAQ Stock Exchange Global Select Market)

17.30 USD
+0.40 (+2.37%)
As of Feb 24
chart
Previous Close 16.90
Open 17.00
Volume 430,275
3m Avg Volume 212,669
Today’s High 17.45
Today’s Low 16.70
52 Week High 19.20
52 Week Low 11.85
Shares Outstanding (mil) 76.23
Market Capitalization (mil) 987.19
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
139
FY16
110
FY15
90
EPS (USD)
FY17
-1.220
FY16
-0.311
FY15
-1.307
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
8.70
5.77
Price to Book (MRQ)
vs sector
2.55
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-11.12
14.43
Return on Equity (TTM)
vs sector
-12.38
16.13

EXECUTIVE LEADERSHIP

Craig Wheeler
President, Chief Executive Officer, Director, Since 2006
Salary: $689,179.00
Bonus: --
Scott Storer
Chief Financial Officer, Senior Vice President, Since 2016
Salary: $40,385.00
Bonus: --
Ganesh Kaundinya
Chief Operating Officer, Chief Scientific Officer, Since 2017
Salary: $433,350.00
Bonus: --
Bruce Leicher
Senior Vice President, General Counsel, Secretary, Since 2008
Salary: $414,655.00
Bonus: --
Bruce Downey
Independent Director, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

675 W Kendall St
CAMBRIDGE   MA   02142-1110

Phone: +1617.4919700

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

SPONSORED STORIES